Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Income from Continuing Operations: 2020-2025

Historic Income from Continuing Operations for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -$21.0 million.

  • Silence Therapeutics' Income from Continuing Operations rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 15.29%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
  • As of Q3 2025, Silence Therapeutics' Income from Continuing Operations stood at -$21.0 million, which was up 23.38% from -$27.4 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Income from Continuing Operations ranged from a high of $12.3 million in Q4 2024 and a low of -$35.5 million during Q3 2024.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$18.6 million (2023), whereas its average is -$16.8 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first spiked by 166.23% in 2024, then crashed by 1,134.00% in 2025.
  • Quarterly analysis of 5 years shows Silence Therapeutics' Income from Continuing Operations stood at -$15.1 million in 2021, then declined by 16.64% to -$17.7 million in 2022, then fell by 5.23% to -$18.6 million in 2023, then soared by 166.23% to $12.3 million in 2024, then spiked by 41.04% to -$21.0 million in 2025.
  • Its last three reported values are -$21.0 million in Q3 2025, -$27.4 million for Q2 2025, and -$28.5 million during Q1 2025.